Specific intestinal fungi play role in the pathogenesis of MASLD and cardiovascular disease
Background and aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for cardiovascular disease (CVD).…
Toxic RNA drives progressive heart damage in myotonic dystrophy
Myotonic dystrophy type 1 (DM1) is the most common cause of adult-onset muscular dystrophy, a genetic disorder that…
New algorithm enables precise subtyping of metabolic liver disease
Metabolic-associated steatotic liver disease (MASLD) is a clinically heterogeneous condition with highly variable outcomes affecting more than 30%…
New fragmentome technology can detect early liver fibrosis and cirrhosis
Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free…
How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…
New pathway found connecting liver congestion to fibrosis and cancer
Researchers from The University of Osaka find that chronic liver congestion is linked to severe liver diseases through…
Artificial lung keeps patient alive after lung removal
By replacing both breathing and circulatory buffering, a novel artificial lung bought critical time after lung removal, revealed…
Updated newborn screening guidelines aim to improve cystic fibrosis detection
An updated report on cystic fibrosis (CF) from Ann & Robert H. Lurie Children’s Hospital of Chicago, in…
Preclinical study reveals potential new treatment for severe liver fibrosis
Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis – a dangerous, disease-induced build-up of…
Single-cell RNA-seq reveals FBLN7’s role in adipose tissue fibrosis
Fibrosis, resulting from excess extracellular matrix (ECM) deposition, is a feature of adipose tissue (AT) dysfunction and obesity-related insulin resistance.…
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve…
Blocking immune cell signals reduces scar tissue formation in wounds
Researchers at the University of Arizona uncovered a previously unknown population of circulating immune cells that play a…